This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Rodney Lax, Ph.D.
Business Development Consultant at Enzytag BV

Profile

I was born in Liverpool (UK) and studied Biochemistry at the University of Birmingham and the Chester Beatty Institute in London (UK) before moving to Germany in 1970. In Germany I worked as a biochemist in the field of steroid endocrinology at the University of Ulm from 1970 – 1975 and from 1975 – 1986 at the University of Essen. I received my “Habilitation’ (Lectureship) in Physiological Chemistry in 1978 and became an Associate Professor at the University of Essen in 1985.

Starting in 1986, I worked for a number of small biotech companies in Northern Germany involved in peptide manufacture including Bissendorf Peptides GmbH, Saxon Biochemicals GmbH (a subsidiary of Bachem California, Inc), and WHERL, where I became CEO in 1997.  After WHERL was acquired by the PolyPeptide Group in 1998, I became Director of Sales & Marketing at PolyPeptide Laboratories GmbH. In February 2003, I moved to PolyPeptide Laboratories, Inc. in Torrance, where I became Senior Director of Business Development, North America.

In January 2014 I retired from full-time employment and am working as a self-employed Business Development Consultant. My main client currently is EnzyTag B.V.

I have been a member of the TIDES Advisory Committee, on the Scientific Advisory Board of the Boulder Peptide Society, and a Director of the Peptide Therapeutics Foundation.

I have published over 50 full papers, mainly related to steroid endocrinology.  More recently I have written articles on peptides for technical journals distributed to the pharmaceutical industry. My most recent major publication is Lax, E.R. & Shah, T. in Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls (Ed: Ved Srivastava, Royal Society of Chemistry) 2019, pp. 151 – 193. Economic and Environmental Factors Affecting the Sustainability of Peptide Therapeutic Manufacturing.

I am a citizen of both the UK and Germany but reside mainly in California.

Agenda Sessions

  • The Case for Chemo-enzymatic Synthesis (CEPS) in the Commercial Manufacture of Therapeutic Peptides

    4:00am